7 active not recruiting, 6 recruiting, 5 completed, 4 not yet recruiting. 6 Phase 3, 5 Phase 2, 4 Phase 1, 2 Early Phase 1, 2 Phase 4.
Follow lecanemab: new trials by email Literature Review of lecanemab trials Research Report on lecanemab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation System for Lecanemab Efficacy Using Gold Electrode ECL to Monitor Alzheimer's Biomarkers Lecanemab - Alzheimer Disease | Phase 4 | Recruiting | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | 100 | 2026-07-10 | 2026-07-07 |
| Amyloid Monoclonal Antibody Treatment in PD Patients With Coexistent AD Pathology Lecanemab, Lecanemab non-administration group - Parkinson Disease | Not applicable | Not yet recruiting | Yonsei University | 60 | 2026-05-01 | 2026-04-22 |
| Efficacy of Lecanemab at Different Therapeutic Doses for Alzheimer's Disease (AD) in Real-World Practice Lecanemab 10 mg/kg, Lecanemab 5-10mg/kg - Alzheimer Disease (AD), Alzheimer Dementia | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 140 | 2026-04-30 | 2026-04-01 | |
| Evaluating the Efficacy and Safety of Lecanemab in Alzheimer's Disease Through Multi-omics Approachs Lecanemab 10 mg/kg, Conventional anti-dementia treatment group - Alzheimer s Disease, Alzheimer Dementia (AD) | Phase 4 | Recruiting | First Affiliated Hospital of Wenzhou Medical University | 200 | 2026-01-01 | 2026-05-22 |
| The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Disease Who Are Currently Treated With Lecanemab. X/T + X-EC, Placebo, Lecanemab 10 mg/kg - Alzheimers Disease | Phase 2 | Not yet recruiting | Neurology Office of South Florida | 60 | 2025-12-01 | 2025-10-08 |
| Therapeutic Efficacy of Monoclonal Antibody Drugs for Alzheimer's Disease Based on PET Research Lecanemab 10 mg/kg, Conventional anti-dementia treatment group - Alzheimer Disease (AD), Alzheimer Dementia | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 120 | 2025-09-01 | 2025-09-03 | |
| Near-Infrared Light Therapy Combined With Lecanemab for Mild Alzheimer's Disease NirsCure with Lecanemab, sham NirsCure with Lecanemab - Alzheimer Disease | Early Phase 1 | Recruiting | Xuanwu Hospital, Beijing | 20 | 2025-05-28 | 2025-09-09 |
| Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry Anti-amyloid Monoclonal Antibodies (mAbs), Standard of Care - Alzheimer Disease | Enrolling by invitation | Emory University | 735 | 2025-03-06 | 2026-07-10 | |
| A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease E2814, Lecanemab, Placebo - Alzheimer's Disease | Phase 2 | Active not recruiting | Eisai Inc. | 105 | 2024-09-30 | 2026-02-11 |
| Deep Cervical Lymphatlc-Venous Anastomosis Surgery for the Treatment of Alzheimer's Disease: A Pilot Study (DIVA Study) Deep Cervical lymphatlc-Venous Anastomosis Surgery, Lecanemab - Alzheimer's Disease | Phase 3 | Recruiting | Zhejiang Provincial People's Hospital | 60 | 2024-07-01 | 2025-01-16 |
| Prospective Cohort Study of Patients With Early Alzheimer's Disease Treated With Lecanemab Lecanemab 10 mg/kg - Alzheimer Disease, Mild Cognitive Impairment (MCI) | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 120 | 2024-06-28 | 2025-09-03 | |
| DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease lecanemab - Alzheimer's Disease, Dementia | Phase 3 | Active not recruiting | Washington University School of Medicine | 40 | 2024-06-10 | 2026-07-27 |
| Feasibility of Lecanemab Registry and Clinical Outcome Measures Lecanemab - Alzheimer Disease | Enrolling by invitation | HealthPartners Institute | 20 | 2024-01-02 | 2026-01-28 | |
| Cognitive Neurology Unit Clinical Registry Lecanemab - Alzheimer Disease | Recruiting | Beth Israel Deaconess Medical Center | 500 | 2023-07-16 | 2026-04-13 | |
| A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Lecanemab - Healthy Volunteers | Phase 1 | Completed | Eisai Inc. | 160 | 2022-09-06 | 2023-01-18 |
| Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy Aducanumab, Exablate Model 4000 Type 2, Lecanemab - Mild Cognitive Impairment, Alzheimer Disease 1 | Early Phase 1 | Active not recruiting | Ali Rezai | 15 | 2022-07-14 | 2026-01-22 |
| Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) E2814, Lecanemab, Matching Placebo (E2814) - Alzheimers Disease, Dementia | Phase 2 / Phase 3 | Active not recruiting | Washington University School of Medicine | 197 | 2021-12-22 | 2026-07-27 |
| A Study of Subcutaneous Lecanemab in Healthy Participants Lecanemab - Healthy Volunteers | Phase 1 | Completed | Eisai Inc. | 60 | 2021-09-07 | 2022-01-19 |
| AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid Lecanemab, Placebo - Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease | Phase 3 | Active not recruiting | Eisai Inc. | 1400 | 2020-07-14 | 2026-06-04 |
| A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease Lecanemab IV, Placebo, Lecanemab SC - Early Alzheimer's Disease | Phase 3 | Active not recruiting | Eisai Inc. | 1906 | 2019-03-27 | 2026-10-06 |
Showing 20 of 24. Sign in to see all of them.
Alzheimer Disease (20) · Cognitive Dysfunction (6) · Dementia (3) · Alzheimer disease type 1 (1) · Parkinson Disease (1)
Eisai Inc. (7) · Second Affiliated Hospital, Zhejiang University, School of Medicine (3) · Washington University School of Medicine (3) · Ali Rezai (1) · Beth Israel Deaconess Medical Center (1) · Eisai Co., Ltd. (1) · Emory University (1) · First Affiliated Hospital of Wenzhou Medical University (1) · HealthPartners Institute (1) · Neurology Office of South Florida (1) · The Fourth Affiliated Hospital of Zhejiang University School of Medicine (1) · Xuanwu Hospital, Beijing (1) · Yonsei University (1) · Zhejiang Provincial People's Hospital (1)
United States (14) · China (7) · Japan (7) · United Kingdom (6) · Australia (5) · Canada (5) · Spain (5) · France (4) · Germany (4) · Italy (4) · Netherlands (3) · South Korea (3) · Argentina (2) · Brazil (2) · Colombia (2)
Randall J Bateman, MD (3) · Ali Rezai, MD, FAANS (1) · Baorong Zhang, M.D. (1) · Bhavani Kashyap, MBBS, PhD (1) · Brian Costell, MD (1) · James J Lah, MD, PhD (1) · Yi Tang, MD, PhD (1)
PMID 38940656, PMID 40042496, PMID 27048170, PMID 33865446, PMID 36449413, PMID 36482412, PMID 36544184, PMID 37009976, PMID 37017737, PMID 37040116, PMID 37131229, PMID 37932961, PMID 38087949, PMID 38629508, PMID 38730496, PMID 39575854, PMID 39974075, PMID 40120616, PMID 40985290, PMID 41170658, PMID 41325201, PMID 41689888, PMID 42552749
R01AG046179 (2), R01AG053267 (2), R56AG053267 (2), U01AG042791 (2), U01AG059798 (2), 2018 (1), R01AG054029 (1), R01AG061848 (1), R01AG068319 (1)